Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

NPS+ Psoriatic Arthritis (US) 2019

Product Code:
s_596201414
Publication Date:
August 2019
Format:
PDF
Price:
€2695

Unique product-level analysis for improving brand health and clinician satisfaction in the US

  • How loyal are clinicians to specific brands?
  • How do leading clinicians rate key psoriatic arthritis brands?
  • What brand messages resonate with Promoters, Passives and Detractors?
  • What is the market share of leading brands among Promoters and Detractors?

Clinicians treating psoriatic arthritis have a number of effective therapy options, but not all make the same choices. What drives clinician prescribing and decision making and why are some more loyal to certain brands than others?

This and other key questions are answered in this insightful August 2019 Net Promoter Score®1 (NPS) analysis of 12 leading psoriatic arthritis brands. Based on the results of an in depth survey of 100 US-based dermatologists and rheumatologists, NPS+ (US) Psoriatic Arthritis identifies the drivers that build clinician satisfaction and brand loyalty.

Buy Now

Buy and Download this report

Leading brands covered in this report

  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Amgen)
  • Humira (adalimumab; AbbVie)
  • Remicade (infliximab; Janssen Biotech)
  • Simponi (golimumab; Janssen Biotech)
  • Orencia (abatacept; Bristol-Myers Squibb)
  • Xeljanz (tofacitinib; Pfizer)
  • Cosentyx (secukinumab; Novartis)
  • Otezla (apremilast; Celgene)
  • Stelara (ustekinumab; Janssen Biotech)
  • Taltz (ixekizumab; Eli Lilly)
  • Tremfya (guselkumab; Janssen Biotech)

This NPS analysis answers important brand questions

  • What underpins the high-ranking NPS scores for Humira, Cosentyx and Enbrel?
  • How brand-loyal are clinicians and which brands are at risk of clinicians switching to a competitor?
  • Overall, how satisfied are clinicians with available brands and what new opportunities exist?
  • What is the market share of Taltz, Cimzia and Tremfya among promoters and detractors?
  • Cost effective? Convenient administration? Slows disease progression? What messages are resonating with Detractors, Passives and Promoters for Stelara, Remicade, Orencia and Xeljanz?

FirstView NPS+ takes you deeper than the standard NPS analysis

Since its introduction in 2003, the Net Promoter Score system has become established as a key metric for assessing user satisfaction and loyalty to brands. But while NPS helps you measure overall brand health, it doesn't tell you how to improve it. NPS+ adds much needed detail and gives you deep insights into:

  • The value of specific brands to Promoters
  • Messages Promoters, Passives and Detractors associate with brands
  • Brands that are at risk of losing out to competitors
  • Brand loyalty, and what drives it

Exclusive to FirstView and not available elsewhere, NPS+ does more than measure your brand’s overall health—it shows you what drives brand satisfaction so you can take action to improve physician engagement and use.

About the Dermatologists and Rheumatologists surveyed

This detailed analysis—based on a survey of 100 US dermatologists and rheumatologists who play an active role in writing prescriptions for their psoriatic arthritis patients—establishes which therapies they use and the clinical characteristics that influence their choices.

This report gives you...

  • 31 clear, easy to read charts that provide at-a-glance understanding of the survey findings
  • Practical data to understand how dermatologists and rheumatologists rank leading therapies
  • Actionable data for addressing negative brand perceptions

What are Net Promoter Scores?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses, given on a scale of 0 to 10, are used to classify doctors into 3 categories:

  • Detractors are those who answer 0 - 6
  • Passives are those who answer 7 - 8
  • Promoters are those who answer 9 - 10

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other PSORIATIC ARTHRITIS reports available

NPS+ Psoriatic Arthritis Europe

Medical Affairs Reputations US: Psoriatic Arthritis

Medical Affairs Reputations Europe: Psoriatic Arthritis

Market Access Impact US: Psoriatic Arthritis

Market Access Impact Europe: Psoriatic Arthritis

To learn about our cost effective Psoriatic Arthritis intelligence package of all reports, please contact us at info@fwreports.com

1NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved